Resources
13 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 9/1/2021 (updated 4/2/2024)
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 12/9/2020 (updated 4/3/2024)
State policymakers are interested in learning about the most effective treatments to address OUD and avoid unintended consequences such as overdose events, mortality from overdose, and use of illicit and unregulated drugs. This article describes the lack of evidence surrounding the use of Medically Supervised Withdrawal as a standalone “treatment.”
Posted 10/14/2021 (updated 4/3/2024)
Presenters explained the role of RH in the continuum of care in this exciting and interactive presentation on emerging topics related to integrating social and medical models of recovery. They focused on emerging issues in rural America resulting from the pandemic, its impact on the rates of substance use disorder (SUD), and use of RH. Presenters emphasized funding for the development of RH, the role of partnerships within the recovery ecosystem, and promising practices involving cross-sector collaboration in housing, corrections, treatment, and recovery supports.
Milena Stott, LICSW, SUDP, The Fletcher Group
Erica Walker, CSW, TCADC, The Fletcher Group
Posted 11/11/2021 (updated 4/3/2024)
This session provided participants with realistic and achievable steps to help consortiums leverage their RCORP-Planning efforts to achieve long-lasting sustainable impact. Participants heard from two RCORP-Planning III sites that are successfully navigating and securing sustainability for their communities using different approaches.
Posted 9/29/2021 (updated 4/3/2024)
In this re-welcome session, HRSA Project Officers shared reminders and updates about grant deliverables, the Evaluation Team will gave updates, and Technical Expert Leads discussed new and ongoing technical assistance available to Implementation I, Implementation II and MAT-Expansion grantees.
Posted 1/12/2021 (updated 4/4/2024)
This handbook is for anyone looking for help or information, and for people who care about them, who may be: Misusing prescription pain medications, using narcotics, heroin, or other opioid drugs; thinking about seeking help for an opioid problem; or Considering medications that help with recovery from opioid use disorder.